Innate Pharma (IPHYF) Payables (2017 - 2025)

Innate Pharma's Payables history spans 9 years, with the latest figure at $17.5 million for Q4 2025.

  • For Q4 2025, Payables rose 2.37% year-over-year to $17.5 million; the TTM value through Dec 2025 reached $17.5 million, up 2.37%, while the annual FY2025 figure was $17.5 million, 1.07% up from the prior year.
  • Payables reached $17.5 million in Q4 2025 per IPHYF's latest filing, up from $17.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $32.7 million in Q4 2021 to a low of $17.1 million in Q4 2024.
  • Average Payables over 5 years is $21.4 million, with a median of $18.3 million recorded in 2023.
  • Peak YoY movement for Payables: plummeted 34.73% in 2022, then increased 2.37% in 2025.
  • A 5-year view of Payables shows it stood at $32.7 million in 2021, then tumbled by 34.73% to $21.3 million in 2022, then fell by 14.17% to $18.3 million in 2023, then decreased by 6.58% to $17.1 million in 2024, then increased by 2.37% to $17.5 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Payables are $17.5 million (Q4 2025), $17.1 million (Q4 2024), and $18.3 million (Q4 2023).